Figure 5From: Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic goutAnti-pegloticase antibody (Ab) titer when serum uric acid (sUA) first exceeded 6 mg/dL and the highest titer subsequently detected during the randomized controlled trial. Both sUA and Ab titers were measured in the same samples from patients defined as nonresponders.Back to article page